OTTAWA, Ontario--(BUSINESS WIRE)--Jul. 15, 2013--
Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and
services to the global health science market, today announced that it
has completed the divestiture of its Targeted Therapies business to BTG
plc (LSE: BTG), an international specialist healthcare company based in
London, United Kingdom for a cash purchase price of US$200 million.
Nordion intends to provide an update in respect to its use of net
transaction proceeds within the next 60 days.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a
global health science company that provides market-leading products used
for the prevention, diagnosis and treatment of disease. We are a leading
provider of medical isotopes and sterilization technologies that benefit
the lives of millions of people in more than 40 countries around the
world. Our products are used daily by pharmaceutical and biotechnology
companies, medical-device manufacturers, hospitals, clinics and research
laboratories. Nordion has approximately 450 highly skilled employees in
three locations. Find out more at www.nordion.com
and follow us at http://twitter.com/NordionInc.
This news release contains
"forward-looking statements" relating to an intended update regarding
the use of the net transaction proceeds that are not historical facts.
Such statements are subject to known and unknown important risks,
uncertainties, assumptions and other factors that may cause actual
results or events to differ materially from the forward-looking
statements in this news release.
The forward-looking statements contained in this news release are made
as of the date of this release and, accordingly, are subject to change
after such date. Except as may be required by securities laws, we do not
undertake any obligation to update or revise any forward-looking
statements contained in this news release, whether as a result of new
information, future events or otherwise. Additionally, we undertake no
obligation to comment on expectations of, or statements made by, third
parties in respect of the intended update regarding the use of the net
For additional information with respect to certain of these and other
beliefs, assumptions, risks and uncertainties, please refer to Nordion’s
Annual Information Form for fiscal 2012 available on SEDAR at www.sedar.com
and on EDGAR on www.sec.gov.
These documents are also available on Nordion’s website at www.nordion.com.
Source: Nordion Inc.
Ana Raman, (613) 595-4580
Maclean, (613) 592-3400 x. 2414